Clinical Report: 2026 ASCO Breast Cancer Highlights: persevERA

Overview

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the phase III persevERA trial and oral selective estrogen receptor degraders (SERDs) in metastatic breast cancer. The supplied trial summary reports that first-line giredestrant plus palbociclib produced a numerical progression-free survival improvement over letrozole plus palbociclib, but did not meet the prespecified threshold for statistical significance.

Background

Endocrine therapy combined with a CDK4/6 inhibitor is a foundational first-line approach for endocrine-sensitive metastatic hormone receptor–positive, HER2-negative breast cancer, according to the supplied guideline summary. Oral SERDs are being studied as estrogen receptor–targeted treatments in this setting and in later lines of therapy. The related SABCS 2025 material describes the lidERA trial of giredestrant in adjuvant treatment of moderate- to high-risk early breast cancer, a distinct clinical setting from metastatic disease. The available context does not provide detailed persevERA methods, participant characteristics, or numerical efficacy and safety results.

Data Highlights

Study or source	Population or setting	Treatment comparison	Reported finding
persevERA BC, phase III	First-line ER-positive/HER2-negative locally advanced or metastatic breast cancer	Giredestrant plus palbociclib versus letrozole plus palbociclib	Numerical improvement in progression-free survival; prespecified threshold for statistical significance was not met. Numerical estimates were not provided in the supplied context.
lidERA, as described in related SABCS 2025 context	Moderate- to high-risk early breast cancer, regardless of ESR1 mutation status	Giredestrant versus standard endocrine therapy	Trial and primary endpoint of invasive disease-free survival are mentioned; outcome data were not supplied.

Key Findings

persevERA BC evaluated giredestrant plus palbociclib against letrozole plus palbociclib as first-line treatment for ER-positive/HER2-negative locally advanced or metastatic breast cancer.
Investigators reported a numerical progression-free survival improvement with giredestrant plus palbociclib, but the result did not meet the prespecified threshold for statistical significance.
The supplied context does not include the trial’s numerical progression-free survival estimates, confidence intervals, safety findings, or detailed subgroup results.
The related lidERA trial studied adjuvant giredestrant versus standard endocrine therapy in moderate- to high-risk early breast cancer, regardless of ESR1 mutation status; the provided material does not report its results.
The supplied guideline summary describes endocrine therapy plus a CDK4/6 inhibitor as a foundational first-line approach for endocrine-sensitive metastatic HR-positive/HER2-negative disease.

Clinical Implications

The supplied information does not establish a statistically significant progression-free survival advantage for first-line giredestrant plus palbociclib over letrozole plus palbociclib. It also does not provide sufficient trial detail to assess safety, subgroup effects, or how the result should affect individual treatment decisions.

Conclusion

The available persevERA summary reports a numerical progression-free survival improvement with giredestrant plus palbociclib that did not meet the prespecified significance threshold. Further interpretation is limited by the absence of detailed efficacy, safety, and subgroup data in the supplied material.

Related Resources & Content

Conexiant's News Site Is Now MDSpire News.

Trending Now

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

Trending Now

Find topic & conditions by first letter

AACE Endocrinology AI

GI & Hepatology News

IDSA Reporter

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

2026 ASCO Breast Cancer Highlights: persevERA

Recommendations